Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 4NETWORK 2UNKNOWN 1

Study Type

Interventional 2

Sponsor

Cancer Type

Endocrine 1

Conditions

Central Nervous System Neoplasms 27Astrocytoma 15Oligodendroglioma 14Glioblastoma 14Gliosarcoma 12Glioma 11Brain Neoplasms 11Ependymoma 4Spinal Cord Neoplasms 3Neuroblastoma 3Somatostatinoma 2Neoplasm Metastasis 2Melanoma 2Medulloblastoma 2Lymphoma 2Lung Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Adenoma, Islet Cell 2Sarcoma, Ewing 1Rhabdoid Tumor 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Optic Nerve Glioma 1Neurotoxicity Syndromes 1Neuroectodermal Tumors, Primitive 1Leukemia 1Insulinoma 1Glucagonoma 1Glioma, Subependymal 1Gastrointestinal Stromal Tumors 1Gastrinoma 1

Interventions

Temozolomide 2Capecitabine 2motesanib diphosphate 1batifiban 1Octreotide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NETWORK × Adenoma, Islet Cell × Temozolomide × Clear all
NCT01824875 2026-02-25

Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors

Eastern Cooperative Oncology Group

Phase 2 Active not recruiting
144 enrolled 15 charts
Endocrine

Glucagonoma, Insulinoma, Adenoma, Islet Cell, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell

NCT05040360 2025-12-15

Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors

SWOG Cancer Research Network

Phase 2 Recruiting
141 enrolled

Adenoma, Islet Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡